FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308407013> ?p ?o ?g. }

• W4308407013 abstract "<h3>Background</h3> Standard of care after surgery for high-grade gliomas (HGG), including glioblastoma (GBM) and anaplastic astrocytoma, is radiation therapy (RT) and temozolomide (TMZ). Unfortunately, lymphopenia commonly occurs after treatment, leading to decreased survival.^1,2 Concentrations of interleukin-7 (IL-7), a T-cell homeostatic cytokine, are inappropriately low in patients with HGG.³ Our previous work, using murine glioma models, demonstrated that NT-I7 (efineptakin alfa), a long-acting recombinant human IL-7, corrects lymphopenia and improves survival.⁴ Here we examine survival, safety, and change in absolute lymphocyte counts (ALCs) following administration of NT-I7 after concurrent RT/TMZ in patients with newly diagnosed HGG. <h3>Methods</h3> Key inclusion criteria for this Phase I/II study included ALC ≥ 600 cells/mm³. NT-I7 was administered intramuscularly within 2 weeks after completion of concurrent RT/TMZ and then every 12 weeks for up to 4 doses. The primary objective of the Phase I portion was to determine safety and the maximum tolerated dose (MTD) of NT-I7 using a 2-dose accelerated phase, followed by a 3+3 design. The Phase II portion (ongoing) is a double-blind, randomized study of 20 HGG patients (10 per arm) to compare ALC changes after administration of either NT-I7 at the MTD or placebo. Exploratory objectives include immune profiling and survival analysis. <h3>Results</h3> Phase I completed accrual with results as follows: 19 patients enrolled (17 GBM, median age 58.0 years [25-78], median baseline ALC 1000 cells/mm³ [400-2,000], median baseline dexamethasone use 0 mg/day [0-12], cut-off date 7/15/22). Twelve patients (63%) were MGMT promotor unmethylated, as unmethylation is associated with worse survival. The median number of NT-I7 doses administered was 2 [2-4]. NT-I7 was well-tolerated with grade 1/2 injection site reactions (42%) the most common treatment-related adverse event (TRAE). The MTD was 720 mcg/kg due to two grade 3 dose-limiting toxicities at 960 mcg/kg (elevated alanine aminotransferase and back pain). Dose-dependent increases in ALC were observed at 4 weeks (1.3-4.1 times of baseline level), persisting up to 12 weeks. Median progression-free survival (mPFS) was 19.1 months (95%CI: 15.1-NA) and median overall survival (mOS) was 22 months (95%CI: 20.7-NA) in methylated GBM. For the harder-to-treat unmethylated GBM patients, mPFS was 11.2 months (95%CI: 5.4-22.4) and mOS was 16 months (95%CI: 12.3-24.3). Immune profiling of peripheral blood is ongoing. <h3>Conclusions</h3> NT-I7 is well tolerated and is associated with an increase in ALC in HGG patients after chemoradiotherapy. Phase II accrual and immune profiling are ongoing. <h3>Acknowledgements</h3> Funding by NeoImmuneTech, Inc. and Siteman Investment Program, Siteman Cancer Center <h3>Trial Registration</h3> Clinical Trial ID: NCT03687957 <h3>References</h3> Mendez JS, Govindan A, Leong J, Gao F, Huang J, Campian JL. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. <i>J Neurooncol</i>. 2016;<b>127</b>(2):329–35. doi: 10.1007/s11060-015-2037-1. Epub 2016 Jan 4. PMID: 26725885; PMCID: PMC4783226. Campian JL, Piotrowski AF, Ye X, Hakim FT, Rose J, Yan XY, Lu Y, Gress R, Grossman SA. Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide. <i>J Neurooncol</i>. 2017;<b>135</b>(2):343–351. doi: 10.1007/s11060-017-2580-z. Epub 2017 Jul 29. PMID: 28756593. Campian JL, Ye X, Gladstone DE, Ambady P, Nirschl TR, Borrello I, Golightly M, King KE, Holdhoff M, Karp J, Drake CG, Grossman SA. Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. <i>J Neurooncol</i>. 2015;<b>124</b>(2):307–16. doi: 10.1007/s11060-015-1841-y. Epub 2015 Jun 13. PMID: 26070554; PMCID: PMC4696006. Campian JL, Ghosh S, Kapoor V, Yan R, Thotala S, Jash A, Hu T, Mahadevan A, Rifai K, Page L, Lee BH, Ferrando-Martinez S, Wolfarth AA, Yang SH, Hallahan D, Chheda MG, Thotala D. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. <i>Clin Cancer Res</i>. 2022;<b>28</b>(6):1229–1239. doi: 10.1158/1078-0432.CCR-21-0947. PMID: 35031547. <h3>Ethics Approval</h3> Each site’s respective institutional review board approved the study. <h3>Consent</h3> Written informed consent was obtained from each participant prior to any trial related activities." @default.
• W4308407013 created "2022-11-11" @default.
• W4308407013 creator A5001703836 @default.
• W4308407013 creator A5014954988 @default.
• W4308407013 creator A5018706204 @default.
• W4308407013 creator A5018814142 @default.
• W4308407013 creator A5030860493 @default.
• W4308407013 creator A5034837880 @default.
• W4308407013 creator A5043388046 @default.
• W4308407013 creator A5050897838 @default.
• W4308407013 creator A5060952145 @default.
• W4308407013 creator A5077751908 @default.
• W4308407013 creator A5079465721 @default.
• W4308407013 creator A5080536692 @default.
• W4308407013 creator A5088917578 @default.
• W4308407013 creator A5089816080 @default.
• W4308407013 date "2022-11-01" @default.
• W4308407013 modified "2023-10-14" @default.
• W4308407013 title "624 A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy" @default.
• W4308407013 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0624" @default.
• W4308407013 hasPublicationYear "2022" @default.
• W4308407013 type Work @default.
• W4308407013 citedByCount "0" @default.
• W4308407013 crossrefType "proceedings-article" @default.
• W4308407013 hasAuthorship W4308407013A5001703836 @default.
• W4308407013 hasAuthorship W4308407013A5014954988 @default.
• W4308407013 hasAuthorship W4308407013A5018706204 @default.
• W4308407013 hasAuthorship W4308407013A5018814142 @default.
• W4308407013 hasAuthorship W4308407013A5030860493 @default.
• W4308407013 hasAuthorship W4308407013A5034837880 @default.
• W4308407013 hasAuthorship W4308407013A5043388046 @default.
• W4308407013 hasAuthorship W4308407013A5050897838 @default.
• W4308407013 hasAuthorship W4308407013A5060952145 @default.
• W4308407013 hasAuthorship W4308407013A5077751908 @default.
• W4308407013 hasAuthorship W4308407013A5079465721 @default.
• W4308407013 hasAuthorship W4308407013A5080536692 @default.
• W4308407013 hasAuthorship W4308407013A5088917578 @default.
• W4308407013 hasAuthorship W4308407013A5089816080 @default.
• W4308407013 hasBestOaLocation W43084070131 @default.
• W4308407013 hasConcept C126322002 @default.
• W4308407013 hasConcept C126894567 @default.
• W4308407013 hasConcept C141071460 @default.
• W4308407013 hasConcept C142724271 @default.
• W4308407013 hasConcept C143998085 @default.
• W4308407013 hasConcept C204787440 @default.
• W4308407013 hasConcept C27081682 @default.
• W4308407013 hasConcept C2776694085 @default.
• W4308407013 hasConcept C2777389519 @default.
• W4308407013 hasConcept C2778227246 @default.
• W4308407013 hasConcept C2778424827 @default.
• W4308407013 hasConcept C2778880634 @default.
• W4308407013 hasConcept C2779083369 @default.
• W4308407013 hasConcept C2989005 @default.
• W4308407013 hasConcept C31760486 @default.
• W4308407013 hasConcept C502942594 @default.
• W4308407013 hasConcept C509974204 @default.
• W4308407013 hasConcept C71924100 @default.
• W4308407013 hasConcept C90924648 @default.
• W4308407013 hasConceptScore W4308407013C126322002 @default.
• W4308407013 hasConceptScore W4308407013C126894567 @default.
• W4308407013 hasConceptScore W4308407013C141071460 @default.
• W4308407013 hasConceptScore W4308407013C142724271 @default.
• W4308407013 hasConceptScore W4308407013C143998085 @default.
• W4308407013 hasConceptScore W4308407013C204787440 @default.
• W4308407013 hasConceptScore W4308407013C27081682 @default.
• W4308407013 hasConceptScore W4308407013C2776694085 @default.
• W4308407013 hasConceptScore W4308407013C2777389519 @default.
• W4308407013 hasConceptScore W4308407013C2778227246 @default.
• W4308407013 hasConceptScore W4308407013C2778424827 @default.
• W4308407013 hasConceptScore W4308407013C2778880634 @default.
• W4308407013 hasConceptScore W4308407013C2779083369 @default.
• W4308407013 hasConceptScore W4308407013C2989005 @default.
• W4308407013 hasConceptScore W4308407013C31760486 @default.
• W4308407013 hasConceptScore W4308407013C502942594 @default.
• W4308407013 hasConceptScore W4308407013C509974204 @default.
• W4308407013 hasConceptScore W4308407013C71924100 @default.
• W4308407013 hasConceptScore W4308407013C90924648 @default.
• W4308407013 hasLocation W43084070131 @default.
• W4308407013 hasOpenAccess W4308407013 @default.
• W4308407013 hasPrimaryLocation W43084070131 @default.
• W4308407013 hasRelatedWork W165245056 @default.
• W4308407013 hasRelatedWork W2094900768 @default.
• W4308407013 hasRelatedWork W2199003465 @default.
• W4308407013 hasRelatedWork W2283634263 @default.
• W4308407013 hasRelatedWork W2358125876 @default.
• W4308407013 hasRelatedWork W2390408846 @default.
• W4308407013 hasRelatedWork W2410623908 @default.
• W4308407013 hasRelatedWork W2808624194 @default.
• W4308407013 hasRelatedWork W3029090213 @default.
• W4308407013 hasRelatedWork W59994307 @default.
• W4308407013 isParatext "false" @default.
• W4308407013 isRetracted "false" @default.
• W4308407013 workType "article" @default.